Developing software to analyze and predict antibody structures and targets.
Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets
['FUNDING_SBIR_2'] · DNASTAR, INC. · NIH-10915664
This study is working on new software that helps understand the different antibodies your body makes when fighting infections or getting vaccinated, which could lead to better treatments and personalized care for conditions like autoimmune diseases.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DNASTAR, INC. (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10915664 on ClinicalTrials.gov |
What this research studies
This research focuses on creating advanced software that can fully characterize the diverse range of antibodies produced by B cells in response to infections, vaccinations, and diseases. By utilizing techniques such as DNA/RNA sequencing and deep learning, the project aims to assemble and analyze the genetic sequences of antibodies, predicting their structures and potential targets. This could lead to better understanding and treatment of various conditions, including autoimmune diseases and infections. Patients may benefit from improved diagnostics and personalized therapies based on their unique antibody profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or those undergoing treatment for infections where antibody response is critical.
Not a fit: Patients who do not have autoimmune diseases or are not affected by conditions related to antibody responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and diagnostics for patients with autoimmune diseases and other conditions related to antibody responses.
How similar studies have performed: Other research has shown promise in using advanced sequencing and computational methods to analyze antibody repertoires, indicating that this approach has potential for success.
Where this research is happening
MADISON, UNITED STATES
- DNASTAR, INC. — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DURFEE, TIMOTHY J — DNASTAR, INC.
- Study coordinator: DURFEE, TIMOTHY J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.